p27 as a target for cancer therapeutics

Cancer Cell

Volumn 3, Issue 2, 2003, Pages 111-115

  Blain, Stacy W ^a,b   Scher, Howard I ^a   Cordon Cardo, Carlos ^a   Koff, Andrew ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TUMOR SUPPRESSOR PROTEIN;

ALLELE; CANCER THERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON; GENE TARGETING; HUMAN; HYPOPHYSIS; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROTEIN DEGRADATION; REVIEW; WILD TYPE; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; MOUSE; MOUSE MUTANT; NEOPLASM; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0142244118     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00026-6     Document Type: Review

References (43)

1. Achenbach T.V., Slater E.P., Brummerhop H., Bach T., Muller R. Inhibition of cyclin-dependent kinase activity and induction of apoptosis by preussin in human tumor cells. Antimicrob. Agents Chemother. 44:2000;2794-2801.
2. Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F., Barone M.V., Chiappetta G., Vento M.T., Spiezia S., et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Invest. 104:1999;856-874.
3. Barata J.T., Cardoso A.A., Nadler L.M., Boussiotis V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood. 98:2001;1524-1531.
4. -/- cells to signals that trigger apoptosis during pituitary tumor development. Oncogene. 22:2002;361-369.
5. Chauffert B., Correia M., Sergent C. Update on mechanisms of drug resistance. Bull. Cancer. 86:1999;97-103.
6. Chiarle R., Fan Y., Piva R., Boggino H., Skolnik J., Novero D., Palestro G., De Wolf-Peeters C., Chilosi M., Pagano M., Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am. J. Pathol. 160:2002;1457-1466.
7. Ciaprrone M., Yamamoto H., Yao Y., Sgambato A., Cattorett E., Tomita N., Monden T., Rotterdam H., Weinstein I.B. Localization and expression of p27Kip1 in multistage colorectal carcinogenesis. Cancer Res. 58:1998;114-122.
8. Cipriano S.C., Chen L., Burns K.H., Koff A., Matzuk M.M. Inhibin and p27 interact to regulate gonadal tumorigenesis. Mol. Endocrinol. 15:2001;985-986.
9. Cordon-Cardo C., Koff A., Drobnjak M., Capodieci P., Osman I., Millard S.S., Gaudin P.B., Fazzari M., Zhang Z.F., Massagué J., Scher H.I. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 90:1998;1284-1291.
10. de Stanchina E., McCurrach M.E., Zindy F., Shieh S.-Y., Ferbeyre G., Samuelson A.V., Prives C., Roussel M.F., Sherr C.J., Lowe S.W. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev. 12:1998;2434-2442.
11. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27 Kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:2001;222-224.
12. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L., Broudy V., Perlmutter R.M., et al. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell. 85:1996;733-744.
13. Fero M.L., Randel E., Gurley K.E., Roberts J.M., Kemp C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 396:1998;177-180.
14. Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J., Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. USA. 98:2001;5043-5048.
15. Hershko D., Bornstein G., Ben-Izhak O., Carrano A., Pagano M., Krausz M.M., Hershko A. Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 91:2001;1745-1751.
16. Hurteau J.A., Allison B.M., Brutkiewicz S.A., Boebl M.G., Heilman D.K., Bigsby R.M., Harrington M.A. Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(KLp1) in epithelial ovarian cancer. Gynecol. Oncol. 83:2001;292-298.
17. Katner A.L., Hoang Q.B., Gootam P., Jaruga E., Ma Q., Gnarra J., Rayford W. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1). Prostate. 53:2002;77-87.
18. Kip1. Cell. 85:1996;721-732.
19. Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I., Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61:2001;7044-7047.
20. Latres E., Chiarle R., Schulman B.A., Pavletich N.P., Pellicer A., Inghirami G., Pagano M. Role of the F-box protein Skp2 in lymphagenesis. Proc. Natl. Acad. Sci. USA. 98:2001;2515-2520.
21. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.-H., Ciarollo S., Catzavelos C., Beniston R., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8:2002;1153-1160.
22. Liu X., Sun Y., Ehrlich M., Lu T., Kloog Y., Weinberg R.A., Lodish H.F., Henis Y.I. Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene. 19:2000;5926-5935.
23. Lloyd R.V., Erickson L.A., Jin L., Kulig E., Qian X., Cheville J.C., Scheithauer B.W. p27Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 154:1999;313-323.
24. Mamillapalli R., Gavrilova N., Mihaylova V.T., Tsvetkov L.M., Wu H., Zhang H., Sun H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 11:2001;263-267.
25. Marins C.P., Berns A. Loss of p27Kip1 but not p21Cip1 decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 21:2002;3739-3748.
26. Massagué J., Blain S.W., Lo R.S. TGF-b signaling in growth control, cancer and heritable disease. Cell. 103:2000;295-309.
27. Nakayama K., Ishida M., Shirame M., Inomata A., Inoue T., Shishido N., Horii I., Loh D.Y., Nakayama K. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:1996;707-720.
28. Nakayama K.-I., Hatakeyama S., Nakayama K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem. Biophys. Res. Commun. 282:2001;853-860.
29. Park M.S., Rosai J., Nguyen H.T., Capodieci P., Cordon-Cardo C., Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc. Natl. Acad. Sci. USA. 96:1999;6382-6387.
30. Philipp-Staheli J., Payne S.R., Kemp C.J. p27Kip1: Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. 264:2001;148-168.
31. Philipp-Staheli J., Kim K.H., Payne S.R., Gurley K.E., Liggitt D., Longton G., Kemp C.J. Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell. 1:2002;355-368.
32. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:2001;1-10.
33. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
34. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2:2002;103-112.
35. Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., Arteaga C.L. Akt/PKB mediates cell cycle progression by phosphorylation of p27kip1 on threonine157 and modulation of its cellular localization. Nat. Med. 8:2002;1145-1152.
36. Singh S.P., Lipman J., Goldman H. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58:1998;1730-1735.
37. Slingerland J., Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183:2000;10-17.
38. Sotillo R., Dubus P., Martin J., de la Cueva E., Ortega S., Malumbres M., Barbacid M. Wide spectrum of tumors in knock-in mice carrying a cdk4 protein insensitive to Ink4 inhibitors. EMBO J. 20:2001;6637-6647.
39. St Croix B., Florenes V.A., Rak J.W., Flanagan M., Bhattacharya N., Slingerland J.M., Kerbel R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2:1996;1204-1210.
40. Supriatno H.K., Hoque M.O., Bando T., Yoshida H., Sato M. Overexpression of p27(Kip1) induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol. 38:2002;730-736.
41. Tsihlias J., Kapusta L., Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:1999;401-423.
42. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., Vinci F., Chiapetta G., Tsichlis P., Bellacosa A., et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8:2002;1136-1144.
43. Yang H.Y., Zhou B.P., Hung M.C., Lee M.H. Oncogenic signals of Her-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J. Biol. Chem. 275:2000;24735-24739.